These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 29330126

  • 1. Recent progress in the discovery of myeloid differentiation 2 (MD2) modulators for inflammatory diseases.
    Chen L, Fu W, Zheng L, Wang Y, Liang G.
    Drug Discov Today; 2018 Jun; 23(6):1187-1202. PubMed ID: 29330126
    [Abstract] [Full Text] [Related]

  • 2. Arachidonic acid inhibits inflammatory responses by binding to myeloid differentiation factor-2 (MD2) and preventing MD2/toll-like receptor 4 signaling activation.
    Zhang Y, Chen H, Zhang W, Cai Y, Shan P, Wu D, Zhang B, Liu H, Khan ZA, Liang G.
    Biochim Biophys Acta Mol Basis Dis; 2020 May 01; 1866(5):165683. PubMed ID: 31953218
    [Abstract] [Full Text] [Related]

  • 3. Sulforaphane inhibits the engagement of LPS with TLR4/MD2 complex by preferential binding to Cys133 in MD2.
    Koo JE, Park ZY, Kim ND, Lee JY.
    Biochem Biophys Res Commun; 2013 May 10; 434(3):600-5. PubMed ID: 23583403
    [Abstract] [Full Text] [Related]

  • 4. Curcumin Analog L48H37 Prevents Lipopolysaccharide-Induced TLR4 Signaling Pathway Activation and Sepsis via Targeting MD2.
    Wang Y, Shan X, Dai Y, Jiang L, Chen G, Zhang Y, Wang Z, Dong L, Wu J, Guo G, Liang G.
    J Pharmacol Exp Ther; 2015 Jun 10; 353(3):539-50. PubMed ID: 25862641
    [Abstract] [Full Text] [Related]

  • 5. Discovery of caffeic acid phenethyl ester derivatives as novel myeloid differentiation protein 2 inhibitors for treatment of acute lung injury.
    Chen L, Jin Y, Chen H, Sun C, Fu W, Zheng L, Lu M, Chen P, Chen G, Zhang Y, Liu Z, Wang Y, Song Z, Liang G.
    Eur J Med Chem; 2018 Jan 01; 143():361-375. PubMed ID: 29202400
    [Abstract] [Full Text] [Related]

  • 6. Lipopolysaccharide (LPS) directly suppresses growth hormone receptor (GHR) expression through MyD88-dependent and -independent Toll-like receptor-4/MD2 complex signaling pathways.
    Dejkhamron P, Thimmarayappa J, Kotlyarevska K, Sun J, Lu C, Bonkowski EL, Denson LA, Menon RK.
    Mol Cell Endocrinol; 2007 Aug 15; 274(1-2):35-42. PubMed ID: 17601656
    [Abstract] [Full Text] [Related]

  • 7. Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2.
    Kim SY, Koo JE, Seo YJ, Tyagi N, Jeong E, Choi J, Lim KM, Park ZY, Lee JY.
    Br J Pharmacol; 2013 Apr 15; 168(8):1933-45. PubMed ID: 23231684
    [Abstract] [Full Text] [Related]

  • 8. Discovery of new MD2-targeted anti-inflammatory compounds for the treatment of sepsis and acute lung injury.
    Chen G, Xiao B, Chen L, Bai B, Zhang Y, Xu Z, Fu L, Liu Z, Li X, Zhao Y, Liang G.
    Eur J Med Chem; 2017 Oct 20; 139():726-740. PubMed ID: 28858767
    [Abstract] [Full Text] [Related]

  • 9. Discovery of new MD2 inhibitor from chalcone derivatives with anti-inflammatory effects in LPS-induced acute lung injury.
    Zhang Y, Wu J, Ying S, Chen G, Wu B, Xu T, Liu Z, Liu X, Huang L, Shan X, Dai Y, Liang G.
    Sci Rep; 2016 Apr 27; 6():25130. PubMed ID: 27118147
    [Abstract] [Full Text] [Related]

  • 10. Celastrol blocks binding of lipopolysaccharides to a Toll-like receptor4/myeloid differentiation factor2 complex in a thiol-dependent manner.
    Lee JY, Lee BH, Kim ND, Lee JY.
    J Ethnopharmacol; 2015 Aug 22; 172():254-60. PubMed ID: 26116162
    [Abstract] [Full Text] [Related]

  • 11. The molecular basis of the host response to lipopolysaccharide.
    Bryant CE, Spring DR, Gangloff M, Gay NJ.
    Nat Rev Microbiol; 2010 Jan 22; 8(1):8-14. PubMed ID: 19946286
    [Abstract] [Full Text] [Related]

  • 12. Heme induces inflammatory injury by directly binding to the complex of myeloid differentiation protein 2 and toll-like receptor 4.
    Lin J, Lin K, Huang L, Jiang Y, Ding X, Luo W, Samorodov AV, Pavlov VN, Liang G, Qian J, Wang Y.
    Toxicol Lett; 2022 Nov 01; 370():15-23. PubMed ID: 36115635
    [Abstract] [Full Text] [Related]

  • 13. Protective effects of hesperetin on lipopolysaccharide-induced acute lung injury by targeting MD2.
    Ye J, Guan M, Lu Y, Zhang D, Li C, Li Y, Zhou C.
    Eur J Pharmacol; 2019 Jun 05; 852():151-158. PubMed ID: 30807747
    [Abstract] [Full Text] [Related]

  • 14. Licochalcone A protects against LPS-induced inflammation and acute lung injury by directly binding with myeloid differentiation factor 2 (MD2).
    Zhu W, Wang M, Jin L, Yang B, Bai B, Mutsinze RN, Zuo W, Chattipakorn N, Huh JY, Liang G, Wang Y.
    Br J Pharmacol; 2023 Apr 05; 180(8):1114-1131. PubMed ID: 36480410
    [Abstract] [Full Text] [Related]

  • 15. Carbon monoxide down-modulates Toll-like receptor 4/MD2 expression on innate immune cells and reduces endotoxic shock susceptibility.
    Riquelme SA, Bueno SM, Kalergis AM.
    Immunology; 2015 Feb 05; 144(2):321-32. PubMed ID: 25179131
    [Abstract] [Full Text] [Related]

  • 16. New MD2 inhibitors derived from curcumin with improved anti-inflammatory activity.
    Zhang Y, Liu Z, Wu J, Bai B, Chen H, Xiao Z, Chen L, Zhao Y, Lum H, Wang Y, Zhang H, Liang G.
    Eur J Med Chem; 2018 Mar 25; 148():291-305. PubMed ID: 29466778
    [Abstract] [Full Text] [Related]

  • 17. Nicotine Enantioselectively Targets Myeloid Differentiation Protein 2 and Inhibits the Toll-like Receptor 4 Signaling.
    Jiang P, Zhang C, Wang H, Li P, Du X, Wang Y, Lyukmanova E, Lin C, Wang X.
    J Chem Inf Model; 2024 Jul 08; 64(13):5253-5261. PubMed ID: 38973303
    [Abstract] [Full Text] [Related]

  • 18. MD2 mediates angiotensin II-induced cardiac inflammation and remodeling via directly binding to Ang II and activating TLR4/NF-κB signaling pathway.
    Han J, Zou C, Mei L, Zhang Y, Qian Y, You S, Pan Y, Xu Z, Bai B, Huang W, Liang G.
    Basic Res Cardiol; 2017 Jan 08; 112(1):9. PubMed ID: 28013347
    [Abstract] [Full Text] [Related]

  • 19. Human MD2 deficiency-an inborn error of immunity with pleiotropic features.
    Li Y, Yu Z, Schenk M, Lagovsky I, Illig D, Walz C, Rohlfs M, Conca R, Muise AM, Snapper SB, Uhlig HH, Garty BZ, Klein C, Kotlarz D.
    J Allergy Clin Immunol; 2023 Mar 08; 151(3):791-796.e7. PubMed ID: 36462957
    [Abstract] [Full Text] [Related]

  • 20. Myeloid differentiation factor 2 in the heart: Bench to bedside evidence for potential clinical benefits?
    Sumneang N, Apaijai N, Chattipakorn SC, Chattipakorn N.
    Pharmacol Res; 2021 Jan 08; 163():105239. PubMed ID: 33053443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.